Floatz logo

BKM120

Estrogen Receptor-positive Breast Cancer

Washington University School of MedicineSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

77 Active assets in the Estrogen Receptor-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Giredestrant
Hoffmann-La Roche
Phase 3BB

View all 50 →

Same molecule, other indications

BKM120 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
62 / 100
View asset →
glioblastomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →